Tarbox Family Office’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-5,601
Closed -$202K 110
2024
Q4
$202K Hold
5,601
0.03% 107
2024
Q3
$238K Hold
5,601
0.04% 104
2024
Q2
$226K Buy
+5,601
New +$234K 0.04% 100
2023
Q2
Sell
-5,509
Closed -$224K 102
2023
Q1
$224K Buy
5,509
+11
+0.2% +$455 0.05% 91
2022
Q4
$247K Buy
+5,498
New +$249K 0.05% 86
2022
Q3
Sell
-5,514
Closed -$326K 101
2022
Q2
$326K Buy
+5,514
New +$453K 0.07% 82
2021
Q1
Sell
-5,498
Closed -$526K 1173
2020
Q4
$526K Hold
5,498
0.11% 61
2020
Q3
$624K Hold
5,498
0.15% 50
2020
Q2
$544K Hold
5,498
0.14% 50
2020
Q1
$354K Hold
5,498
0.11% 69
2019
Q4
$328K Sell
5,498
-282
-5% -$17.4K 0.09% 85
2019
Q3
$341K Hold
5,780
0.1% 63
2019
Q2
$373K Hold
5,780
0.12% 57
2019
Q1
$367K Buy
5,780
+600
+12% +$31.5K 0.13% 57
2018
Q4
$197K Sell
5,180
-790
-13% -$27.9K 0.08% 82
2018
Q3
$256K Hold
5,970
0.09% 74
2018
Q2
$131K Hold
5,970
0.05% 108
2018
Q1
$30K Hold
5,970
0.01% 199
2017
Q4
$14K Buy
+5,970
New +$18.7K 0.01% 281

Other funds holding TNDM

Tarbox Family Office's TNDM Position: Q1 2025 in Review

Tarbox Family Office sold out of Tandem Diabetes Care (TNDM) in Q1 2025, closing a stake of 5,601 shares — an estimated $202K sold.

Tarbox Family Office first reported a position in TNDM in Q4 2017 and held it in 19 quarters. The position peaked at $624K in Q3 2020. 275 funds tracked by Wall St. Rank hold TNDM as of Q1 2025.

  • Tarbox Family Office reported no remaining Tandem Diabetes Care position as of Q1 2025 after selling out during the quarter.
  • Tarbox Family Office sold 5,601 Tandem Diabetes Care shares in Q1 2025, an estimated $202K.
  • Tarbox Family Office first reported a position in Tandem Diabetes Care in Q4 2017 and held it in 19 quarters.
  • Tarbox Family Office's Tandem Diabetes Care position peaked at $624K in Q3 2020.
  • 275 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2025.

Based on Tarbox Family Office's 13F filing for Q1 2025, filed 8 May 2025.